Absorption and excretion of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in man and dog.
The blood levels and excretion of radioactivity administered as 14C- or 3H-4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) have been studied after oral administration to dogs and man. After a single dose of 14C- or 3H-DA 2370 (10 mg/kg) to dogs the daily loss of radioactivity in urine and faeces fell to less than 1% of the dose in 4 days and the plasma levels showed a biexponential decay with mean half-lives of 3.7 and 62 h. When a single 200 mg dose of 3H-DA 2370 was administered to human subjects maximum urinary excretion of radioactivity occurred during day 2 with 4% of the total during day 5. Maximum faecal excretion was on day 2-3 with 0.5% of the dose on day 7. The plasma half-life was 32.5 h. A similar dose three times a day for 3 days had a half-life of 39 h when dosing ceased; radioactivity in the urine and faeces was 2% and 2.5% of the dose, respectively, 4 days later.
D000328:Adult; D000818:Animals; D004285:Dogs; D005260:Female; D011298:Feprazone / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008297:Male; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D011298:Feprazone; D010653:Phenylbutazone